GlassScriptPhysician profile
David S Weingarden
NPI 1851394654
$588.18
in general payments reported to CMS, 2019-2025
16 companies · $52.36 in 2025
The $52.36 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.46 · 2022: $99.23 · 2023: $315 · 2024: $76.64 · 2025: $52.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $148.12 | 2022-2025 | Briviact, Nayzilam |
| Impel Pharmaceuticals INC. | $77.15 | 2023 | Trudhesa |
| Abbvie INC. | $51.65 | 2022-2023 | Ubrelvy |
| Acorda Therapeutics, INC | $45.17 | 2023 | Inbrija |
| Neurelis, INC. | $37.65 | 2023 | Valtoco |
| Eisai INC. | $30.56 | 2025 | |
| Sk Life Science, INC. | $27.64 | 2022 | |
| Neurocrine Biosciences, INC. | $27.03 | 2024 | Ingrezza |
| Tanabe Pharma America, INC. | $25.57 | 2024 | |
| Bausch Health US, LLC | $25.03 | 2019 | |
| Tg Therapeutics, INC. | $23.77 | 2023 | |
| Acadia Pharmaceuticals INC | $19.43 | 2019 | |
| Genentech USA, INC. | $17.16 | 2023 | Ocrevus |
| Amgen INC. | $17.13 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.12 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weingarden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.